Reflecting on a decade of collaborating excellence: 10 years of neurology at Wieslab AB

A decade ago, an excellent collaboration began for the benefit of neurological diagnostics: Wieslab AB is celebrating its 10th anniversary in neurology ‒ together with EUROIMMUN. We wanted to know what is behind this successful concept and asked Lina Tebbla,…

Der Beitrag Reflecting on a decade of collaborating excellence: 10 years of neurology at Wieslab AB erschien zuerst auf EUROIMMUNBlog.

Reflecting on a decade of collaborating excellence: 10 years of neurology at Wieslab AB

A decade ago, an excellent collaboration began for the benefit of neurological diagnostics: Wieslab AB is celebrating its 10th anniversary in neurology ‒ together with EUROIMMUN. We wanted to know what is behind this successful concept and asked Lina Tebbla, Global Technology Manager from Wieslab: Dear Lina, can you provide an overview of your diagnostic […]

Der Beitrag Reflecting on a decade of collaborating excellence: 10 years of neurology at Wieslab AB erschien zuerst auf EUROIMMUNBlog.

Updated COVID-19 XBB.1.5 vaccines elicit strong immune responses to new SARS-CoV-2 variants

Two new studies on SARS-CoV-2 vaccine immune responses suggest that the XBB.1.5-containing mRNA vaccines most likely increase protection against COVID-19 caused by currently circulating XBB variants and the emerging BA.2.86 variant in healthy persons and in patients on haemodialysis. The studies build on collaborative work between the Hannover Medical School, Germany and EUROIMMUN and were […]

Der Beitrag Updated COVID-19 XBB.1.5 vaccines elicit strong immune responses to new SARS-CoV-2 variants erschien zuerst auf EUROIMMUNBlog.

Updated COVID-19 XBB.1.5 vaccines elicit strong immune responses to new SARS-CoV-2 variants

Two new studies on SARS-CoV-2 vaccine immune responses suggest that the XBB.1.5-containing mRNA vaccines most likely increase protection against COVID-19 caused by currently circulating XBB variants and the emerging BA.2.86 variant in healthy persons and in patients on haemodialysis. The…

Der Beitrag Updated COVID-19 XBB.1.5 vaccines elicit strong immune responses to new SARS-CoV-2 variants erschien zuerst auf EUROIMMUNBlog.

EUROIMMUN’s portfolio for therapeutic drug monitoring is expanding

EUROIMMUN has been offering test systems for therapeutic drug monitoring (TDM) since 2019. Owing to the cooperation with IDS and their range of TDM products from Theradiag, we were able to significantly expand our portfolio: We are now offering ELISA…

Der Beitrag EUROIMMUN’s portfolio for therapeutic drug monitoring is expanding erschien zuerst auf EUROIMMUNBlog.

Immunoblots: an old friend with a new face – An interview with EUROIMMUN

Immunoblots are an important laboratory-diagnostic tool to detect autoimmune diseases, allergies and infectious diseases. They enable monospecific detection of many different antibodies and, simultaneously, their differentiation. Especially autoimmune diseases, such as myositis, may be caused by manifold antibodies– many of…

Der Beitrag Immunoblots: an old friend with a new face – An interview with EUROIMMUN erschien zuerst auf EUROIMMUNBlog.

Ultrafast immunofluorescence microscopy – now with 89 new products for autoimmune and infection diagnostics

Our main goal is to offer our customers not only a broad range of assays, but also a flexible choice of automation solutions. Therefore, this year, we have provided proofs of compatibility for a total of 89 indirect immunofluorescence tests…

Der Beitrag Ultrafast immunofluorescence microscopy – now with 89 new products for autoimmune and infection diagnostics erschien zuerst auf EUROIMMUNBlog.

First newly developed ELISA of risk class B declared IVDR-compliant

Anti-TBE Virus ELISA 2.0 (IgG) After EUROIMMUN received the required certificate for its quality management system in accordance with the new European Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) in May of this year, the first newly…

Der Beitrag First newly developed ELISA of risk class B declared IVDR-compliant erschien zuerst auf EUROIMMUNBlog.

Omicron-induced T- and B-cell immunity in vaccinated and naïve individuals

A recent study has demonstrated substantial differences in SARS-CoV-2 immunity after Omicron infection in triple-COVID-19-vaccinated and antigen-naïve individuals, which may influence cross-protection against future variants. The study was performed as part of a collaboration between the Hannover Medical School, Germany…

Der Beitrag Omicron-induced T- and B-cell immunity in vaccinated and naïve individuals erschien zuerst auf EUROIMMUNBlog.